A.BCR-ABL
B.AML1-MTG8
C.PML-RARA
D.MLL-ENL
E.IL-3-IgH
[单选题]t(8;21)形成的融合基因为A.BCR/ABLB.AML1/ETOC.PML/RARαD.CBFB/MYH11E.DEK/CAN
[单选题]A.ML- M2 是A.BCR/ABLB.AML1/ETOC.PML/RARαD.CBFB/MYH11E.LGK/MYC
[单选题]A.ML- M4是A.BCR/ABLB.AML1/ETOC.PML/RARαD.CBFB/MYH11E.LGK/MYC
[单选题]A.ML- M3是A.BCR/ABLB.AML1/ETOC.PML/RARαD.CBFB/MYH11E.LGK/MYC
[单选题]C.ML 是A.BCR/ABLB.AML1/ETOC.PML/RARαD.CBFB/MYH11E.LGK/MYC
[单选题]A.ML-M4Eo出现的特异的融合基因是A.BCR-ABLB.CBFβ-MYH11C.PML-RARαD.MLL-ENLE.IL-3-IgH
[单选题]大多数AML-M3特异性融合基因是A.bcr/AbLB.PML/RARαC.PLZF-RARαD.NPM-RARαE.DEK-CAN
[单选题]RUNX1-RUNX1T1融合基因阳性见于A.AML-M1B.AML-M2bC.AML-M3D.AML-M4E.AML-M5
[单选题]急性髓细胞白血病AML1-ETO基因可见于A.M1B.M2C.M3D.M4E.M5
[单选题]符合AML-M2b型白血病特点的是A.异常中性中幼粒细胞核浆发育明显不平衡B.α-NBE染色呈阳性反应C.有t(9;22)D.异常早幼粒细胞核浆发育明显不平衡E.CD10为主要免疫标志